
Discovery engine for small molecule modulators of disordered targets
Our science
Nuage Therapeutics mission is to leverage chemical biology and biomolecular condensation to develop selective drugs targeting proteins with disordered regions for challenging indications to improve patient’s life

Our team

Xavier Salvatella
Founder

Mateusz Biesaga
Founder

Denes Hnisz
Founder

Judit Anido
Founder & CEO

Pilar Casado
Chief Financial Officer

Jordina Guillén
Head of Science

Nadia Pons
Head of Corporate Development
Board of Directors

Clara Campàs
Board member

Xavier Salvatella
Board member

Denes Hnisz
Board member

Judit Anido
Board member
Nuage Therapeutics appoints biotech entrepreneur and executive Judit Anido as CEO
May 10, 2022
Nuage Therapeutics, the spin-off from IRB Barcelona and ICREA is launched with the support of Asabys
September 28, 2021
Nuage Therapeutics appoints biotech entrepreneur and executive Judit Anido as CEO
May 10, 2022
Nuage Therapeutics, the spin-off from IRB Barcelona and ICREA is launched with the support of Asabys
September 28, 2021
Private investors:
This company is invested by Innvierte, an investment program of CDTI, E.P.E.
Project grants:




- Nuage Therapeutics has been awarded with the CDTI grant SNEO-2022214, in collaboration with Ministerio de Ciencia e Innovación and cofunded by the European Union–Next Generation EU
- Grant PTQ2021-011994 and PTQ2021-011961 awarded by MCIN/AEI/10.13039/501100011033
Careers
Data Scientist
View details
Lab Technician (protein purification)
View details
Lab Technician (cell biology)
View details
Get in touch

Xavier Salvatella
Founder
ICREA Professor, Leader of the Laboratory of Molecular Biophysics at IRB Barcelona. Expert in intrinsically disordered proteins, biomolecular condensation and the structural and functional properties of the transactivation domain of androgen receptor.

Mateusz Besiaga
Founder
PhD student and MSCA Fellow in the Laboratory of Molecular Biophysics at IRB Barcelona. Biomedical engineer specialised in assay development and validation for drug discovery. Coordinator of the Nuage project in the CaixaResearch Validate accelerator programme of “la Caixa” Foundation.

Denes Hnisz
Founder
Leader of the Precision Gene Control group at the Max Planck Institute for Molecular Genetics in Berlin. Expert in transcriptional control, nuclear condensates and genome structure. Has served as a consultant with startup biotechnology companies in the Boston area.

Georgina Sorrosal
Head of Operations
Biotechnologist with a PhD in Genetics and a Developmental Biology research background. Expertise in science management for 11 years, including venture capital in the healthcare sector, knowledge transfer and innovation in a hospital environment & project management in both public and private biopharma sectors.

Jordina Guillén
Head of Science
Biologist with a PhD in Molecular Biology and 10 years of experience in biomedical research. Expertise in intrinsically disordered proteins, biomolecular condensates and gene expression regulation.

Nadia Pons
Head of Corporate Development
Biologist with a demonstrated track-record managing healthcare cutting-edge innovation projects, technology transfer and strategic innovation. Nadia has more than 10 years of experience working in the public and private health sector with proven scouting, analytics, and negotiation skills to identify and implement disruptive technologies and transformational lines of business that support company’s growth.

Clara Campàs
Chair

Pilar Casado
Chief Financial Officer

Judit Anido
Founder & CEO
Seasoned biotech entrepreneur and executive. Formerly, Co-founder and CEO of Mosaic Biomedicals, a biotech company developing innovative drugs for cancer treatment. After the merger with the Canadian Northern Biologics, also became Vice-President of Operations and Corporate Affairs at Northern. The assets of the companies were acquired by Boehringer Ingelheim and AstraZeneca.
Judit also served as CEO and President of CataloniaBio & HealthTech, the Catalan association of companies in the health sector. Holds a PhD in Biology from the University of Barcelona and an MBA from Duke University (US).